ArticleAmerican journal of translational research2020
miR-638 acts as an oncogene and predicts poor prognosis in renal cell carcinoma.
Article in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- 17β-Estradiol Abrogates TNF-α-Induced Human Brain Vascular Pericyte Migration by Downregulating miR-638 via ER-β.International journal of molecular sciences · 2024Article
- Hsa_circ_0008344 Promotes Glioma Tumor Progression and Angiogenesis Presumably by Regulating miR-638/SZRD1 Pathway.Neurotoxicity research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to investigate the function and prognostic value of miR-638 in renal cell carcinoma (RCC).
methodsExpression of miR-638 in RCC tissues and corresponding noncancerous tissues were examined by reverse transcription quantitative polymerase chain reaction (RT-qPCR). To explore the effects of miR-638 on cell migration, invasion, viability, and apoptosis of RCC cells, wound scratch, transwell, MTT, CCK-8, and flow cytometry assays were performed. Kaplan-Meier and Cox regression analyses were used to evaluate the relationship between miR-638 expression and prognosis of RCC patients. Potential target genes of miR-638 were predicted and validated via multiple bioinformatics analyses.
resultsmiR-638 was upregulated in RCC tissues when compared with corresponding noncancerous tissues (
conclusionsThe results of this study demonstrated that miR-638 functions as an oncogene in RCC and has the potential to be a prognostic biomarker for RCC.
Indexed as
Identifiers
32774724PMC7407746W3049284181What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.